BioNano Genomics Appoints Mike Ward to the Senior Executive Management Team
News May 22, 2014
BioNano Genomics has announced the appointment of Mr. Mike Ward as a member of the senior executive management team and vice president, corporate development. Mr. Ward has more than 20 years of life sciences-dedicated investment banking, venture capital and private equity experience.
"With his impressive track record in mergers and acquisitions as a life sciences-dedicated investment banker and in corporate development for healthcare portfolio companies as a private equity investor, we are confident that Mike will help to further expand the reach of BioNano’s technology and commercialization. Mike has dedicated his career over the past two decades to creating value-added strategic transaction opportunities for life sciences companies," said Erik Holmlin, president and CEO of BioNano Genomics.
Holmlin continued, "Mike will be a great addition to the senior management team as we further advance BioNano Genomics as the leading provider of genome mapping technology and continue to accelerate placement of Irys instruments globally."
Before joining BioNano Genomics, Mr. Ward was at Lurie Investment Fund where he was responsible for managing the life sciences venture capital and private equity investments of the Lurie family.
Mr. Ward guided senior executive management teams of Lurie’s life sciences portfolio companies in conducting business and corporate development, clinical and regulatory strategy, commercialization planning, intellectual property management, M&A and financings. During his tenure, he also served on the boards of a number of life sciences portfolio companies on behalf of Lurie.
Prior to joining Lurie Investment Fund in 2009, Mr. Ward gained more than 15 years of investment banking experience at Leerink Partners, Credit Suisse, Dresdner Kleinwort Wasserstein, BMO and Vector Securities.
During his career in investment banking, Mr. Ward executed more than 80 life sciences mergers, acquisitions, divestitures, strategic alliances, private placements, IPOs and follow-on public offerings.
In his more than two decades of experience fostering the development of life sciences companies, he focused predominantly on medical technology, tools, diagnostics and biopharmaceutical markets.
Forensic Facial Reconstruction Could Now Look to Your DNANews
Researchers have identified fifteen genes that determine our facial features. The potential applications are numerous. Doctors could use DNA for skull and facial reconstructive surgery, forensic examiners could sketch a perpetrator’s face on the basis of DNA retrieved from a crime scene, and historians would be able to reconstruct facial features using DNA from days long gone.READ MORE
Duplicate Genes Offer a Explanation for Differences Between the SexesNews
A study in flies has identified the process by duplicating a gene can help resolve genetic sexual conflict.READ MORE
Inheritance and Cannibalism Shape the Termite Gut MicrobiomeNews
A huge new study has outlined what influences help create the incredibly diverse termite microbiome.READ MORE
Comments | 0 ADD COMMENT
3rd Annual Bioprocessing of Advanced Cellular Therapies
May 29 - May 30, 2018